248 related articles for article (PubMed ID: 7473131)
1. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis.
Cherwinski HM; Cohn RG; Cheung P; Webster DJ; Xu YZ; Caulfield JP; Young JM; Nakano G; Ransom JT
J Pharmacol Exp Ther; 1995 Nov; 275(2):1043-9. PubMed ID: 7473131
[TBL] [Abstract][Full Text] [Related]
2. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans.
Rückemann K; Fairbanks LD; Carrey EA; Hawrylowicz CM; Richards DF; Kirschbaum B; Simmonds HA
J Biol Chem; 1998 Aug; 273(34):21682-91. PubMed ID: 9705303
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of action of leflunomide in rheumatoid arthritis.
Fox RI
J Rheumatol Suppl; 1998 Jul; 53():20-6. PubMed ID: 9666414
[TBL] [Abstract][Full Text] [Related]
4. The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism.
Cherwinski HM; McCarley D; Schatzman R; Devens B; Ransom JT
J Pharmacol Exp Ther; 1995 Jan; 272(1):460-8. PubMed ID: 7529314
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production.
Siemasko K; Chong AS; Jäck HM; Gong H; Williams JW; Finnegan A
J Immunol; 1998 Feb; 160(4):1581-8. PubMed ID: 9469413
[TBL] [Abstract][Full Text] [Related]
6. Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide--mechanisms independent of pyrimidine depletion.
Korn T; Magnus T; Toyka K; Jung S
J Leukoc Biol; 2004 Nov; 76(5):950-60. PubMed ID: 15328336
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of action of leflunomide: in vivo uridine administration reverses its inhibition of lymphocyte proliferation.
Silva HT; Cao W; Shorthouse R; Morris RE
Transplant Proc; 1996 Dec; 28(6):3082-4. PubMed ID: 8962193
[No Abstract] [Full Text] [Related]
8. Leflunomide analogue FK778 is vasculoprotective independent of its immunosuppressive effect: potential applications for restenosis and chronic rejection.
Savikko J; Von Willebrand E; Häyry P
Transplantation; 2003 Aug; 76(3):455-8; discussion 471-3. PubMed ID: 12923428
[TBL] [Abstract][Full Text] [Related]
9. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases.
Herrmann ML; Schleyerbach R; Kirschbaum BJ
Immunopharmacology; 2000 May; 47(2-3):273-89. PubMed ID: 10878294
[TBL] [Abstract][Full Text] [Related]
10. Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis?
Fairbanks LD; Rückemann K; Qiu Y; Hawrylowicz CM; Richards DF; Swaminathan R; Kirschbaum B; Simmonds HA
Biochem J; 1999 Aug; 342 ( Pt 1)(Pt 1):143-52. PubMed ID: 10432311
[TBL] [Abstract][Full Text] [Related]
11. Restriction of de novo pyrimidine biosynthesis inhibits Th1 cell activation and promotes Th2 cell differentiation.
Dimitrova P; Skapenko A; Herrmann ML; Schleyerbach R; Kalden JR; Schulze-Koops H
J Immunol; 2002 Sep; 169(6):3392-9. PubMed ID: 12218161
[TBL] [Abstract][Full Text] [Related]
12. The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1.
Urushibara M; Takayanagi H; Koga T; Kim S; Isobe M; Morishita Y; Nakagawa T; Löeffler M; Kodama T; Kurosawa H; Taniguchi T
Arthritis Rheum; 2004 Mar; 50(3):794-804. PubMed ID: 15022321
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide.
Greene S; Watanabe K; Braatz-Trulson J; Lou L
Biochem Pharmacol; 1995 Sep; 50(6):861-7. PubMed ID: 7575649
[TBL] [Abstract][Full Text] [Related]
14. Inhibiting the teratogenicity of the immunosuppressant leflunomide in mice by supplementation of exogenous uridine.
Fukushima R; Kanamori S; Hirashiba M; Hishikawa A; Muranaka R; Kaneto M; Kitagawa H
Toxicol Sci; 2009 Apr; 108(2):419-26. PubMed ID: 19190124
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo effects of leflunomide, brequinar, and cyclosporine on pyrimidine biosynthesis.
Silva HT; Cao W; Shorthouse RA; Löffler M; Morris RE
Transplant Proc; 1997; 29(1-2):1292-3. PubMed ID: 9123312
[No Abstract] [Full Text] [Related]
16. Dihydroorotate dehydrogenase is a target for the biological effects of leflunomide.
Williamson RA; Yea CM; Robson PA; Curnock AP; Gadher S; Hambleton AB; Woodward K; Bruneau JM; Hambleton P; Spinella-Jaegle S; Morand P; Courtin O; Sautés C; Westwood R; Hercend T; Kuo EA; Ruuth E
Transplant Proc; 1996 Dec; 28(6):3088-91. PubMed ID: 8962196
[No Abstract] [Full Text] [Related]
17. Mechanism of the antiproliferative action of leflunomide. A77 1726, the active metabolite of leflunomide, does not block T-cell receptor-mediated signal transduction but its antiproliferative effects are antagonized by pyrimidine nucleosides.
Cao WW; Kao PN; Chao AC; Gardner P; Ng J; Morris RE
J Heart Lung Transplant; 1995; 14(6 Pt 1):1016-30. PubMed ID: 8719445
[TBL] [Abstract][Full Text] [Related]
18. Cell cycle regulation and inhibition of de novo pyrimidine biosynthesis by leflunomide.
Schorlemmer HU; Milbert U; Zeitter D; Haun G; Wunschel M; Bartlett RR
Inflamm Res; 1999 Dec; 48 Suppl 2():S115-6. PubMed ID: 10667841
[No Abstract] [Full Text] [Related]
19. Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives.
Knecht W; Löffler M
Biochem Pharmacol; 1998 Nov; 56(9):1259-64. PubMed ID: 9802339
[TBL] [Abstract][Full Text] [Related]
20. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase.
Davis JP; Cain GA; Pitts WJ; Magolda RL; Copeland RA
Biochemistry; 1996 Jan; 35(4):1270-3. PubMed ID: 8573583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
